摘要
有效治疗痴呆症,如阿尔茨海默氏病(阿尔茨海默病)的前景是渺小的,由于其破坏了关键的高级认知功能的背后的脑途径。有一个重大的转变,在该领域的检测条件,如AD,在他们的最早阶段,这将允许预防或治疗方法,大大降低风险和/或减缓疾病的进展。AD的特点是标志性的病理改变,如胞外Aβ斑块和细胞内神经原纤维病理,选择性地影响神经元和大脑回路的特定子类。目前的证据表明, 在显性痴呆前Aβ 斑块开始用许多年形成,渐进的病理学,提供了一个潜在的早期干预的目标。早期的在大脑中Aβ的变化导致局部损伤树突,对兴奋性突触和投射神经元的过程极易受到攻击。Aβ病理学是一系列的转基因模型中过度表达突变的人类家族性AD的基因复制(如APP、早老素1)。研究与β斑块相关神经炎过程异常再生和退行性改变的发展可能是了解AD和神经元损伤的病理特征之间的关系的最好方式,并制定早期预防、延缓或减轻对Aβ病理和/或导致认知功能障碍的神经改变。
关键词: 阿尔茨海默病,淀粉样前体蛋白,Aß,血小板,营养不良的神经轴突,选择性易损性,转基因小鼠。
Current Alzheimer Research
Title:Defining the earliest pathological changes of Alzheimer’s disease
Volume: 13 Issue: 3
Author(s): James C. Vickers, Stan Mitew, Adele Woodhouse, Carmen M. Fernandez-Martos, Mathew T. Kirkcaldie, Alison J. Canty and Graeme H. McCormack, Anna E. King
Affiliation:
关键词: 阿尔茨海默病,淀粉样前体蛋白,Aß,血小板,营养不良的神经轴突,选择性易损性,转基因小鼠。
摘要: The prospects for effectively treating well-established dementia, such as Alzheimer’s disease (AD), are slim, due to the destruction of key brain pathways that underlie higher cognitive function. There has been a substantial shift in the field towards detecting conditions such as AD in their earliest stages, which would allow preventative or therapeutic approaches to substantially reduce risk and/or slow the progression of disease. AD is characterized by hallmark pathological changes such as extracellular Aβ plaques and intracellular neurofibrillary pathology, which selectively affect specific subclasses of neurons and brain circuits. Current evidence indicates that Aβ plaques begin to form many years before overt dementia, a gradual and progressive pathology which offers a potential target for early intervention. Early Aβ changes in the brain result in localized damage to dendrites, axonal processes and synapses, to which excitatory synapses and the processes of projection neurons are highly vulnerable. Aβ pathology is replicated in a range of transgenic models overexpressing mutant human familial AD genes (eg APP and presenilin 1). Studying the development of aberrant regenerative and degenerative changes in neuritic processes associated with Aβ plaques may represent the best opportunity to understand the relationship between the pathological hallmarks of AD and neuronal damage, and to develop early interventions to prevent, slow down or mitigate against Aβ pathology and/or the neuronal alterations that leads to cognitive impairment.
Export Options
About this article
Cite this article as:
James C. Vickers, Stan Mitew, Adele Woodhouse, Carmen M. Fernandez-Martos, Mathew T. Kirkcaldie, Alison J. Canty and Graeme H. McCormack, Anna E. King , Defining the earliest pathological changes of Alzheimer’s disease , Current Alzheimer Research 2016; 13 (3) . https://dx.doi.org/10.2174/1567205013666151218150322
DOI https://dx.doi.org/10.2174/1567205013666151218150322 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Multimodal Treatment of Acromegaly: Current Status and Future Perspectives
Endocrine, Metabolic & Immune Disorders - Drug Targets A Clinician’s Guide to Monoamine Oxidase Inhibitors
Current Psychiatry Reviews Cardiac Dys-Synchronization and Arrhythmia in Hyperhomocysteinemia
Current Neurovascular Research A Medicinal Mushroom: Phellinus Linteus
Current Medicinal Chemistry Role of Mitochondrial Protein Quality Control in Oxidative Stress-induced Neurodegenerative Diseases
Current Alzheimer Research Circulating Aminopeptidase Activities in Men and Women with Essential Hypertension
Current Medicinal Chemistry Virus Vasculopathy and Stroke: An Under-Recognized Cause and Treatment Target
Infectious Disorders - Drug Targets RNAi for the Treatment of Prion Disease: A Window for Intervention in Neurodegeneration?
CNS & Neurological Disorders - Drug Targets Memory Enhancing Effect of Black Pepper in the AlCl3 Induced Neurotoxicity Mouse Model is Mediated Through Its Active Component Chavicine
Current Pharmaceutical Biotechnology Mitochondrial Triglyceride Transfer Protein Inhibition: New Achievements in the Treatment of Dyslipidemias
Current Pharmaceutical Design Angiogenesis and Blood-Brain Barrier Permeability in Vascular Remodeling after Stroke
Current Neuropharmacology Current Opinions and Perspectives on the Role of Immune System in the Pathogenesis of Parkinson's Disease
Current Pharmaceutical Design Emerging Drugs and Indications for Cardio-Metabolic Disorders in People with Severe Mental Illness
Current Pharmaceutical Design Recent Patents Concerning Modulators of Protein Kinase C
Recent Patents on DNA & Gene Sequences Humanin: A Possible Linkage Between Alzheimer’s Disease and Type 2 Diabetes
CNS & Neurological Disorders - Drug Targets Scope of Lipid Nanoparticles in Neuroscience: Impact on the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Ischemia-Reperfusion Injury of the Cochlea: Pharmacological Strategies for Cochlear Protection and Implications of Glutamate and Reactive Oxygen Species
Current Neuropharmacology Non-Pharmacological Approaches to the Prevention and Treatment of Alzheimer’s Disease with Respect to the Rising Treatment Costs
Current Alzheimer Research Gender Differences in Response to Therapy for Cardiovascular Diseases
Current Pharmacogenomics and Personalized Medicine National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness- Alzheimers Disease (CATIE-AD): Baseline Characteristics
Current Alzheimer Research